Global Lung Cancer Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Lung Cancer Type;
Small cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC).By Diagnostic Test;
Imaging Test, Sputum Cytology, Biopsy, Molecular Tests, and Others.By End Use;
Hospitals and Clinics, Diagnostic Laboratories and, Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Lung Cancer Diagnostics Market (USD Million), 2021 - 2031
In the year 2024, the Global Lung Cancer Diagnostics Market was valued at USD 116,373.74 million. The size of this market is expected to increase to USD 200,610.48 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.1%.
Lung cancer remains one of the most prevalent and deadliest forms of cancer worldwide, prompting significant attention in diagnostics and treatment. The global lung cancer diagnostics market is witnessing remarkable growth, driven by several factors. Firstly, the increasing incidence of lung cancer, particularly among smokers and individuals exposed to environmental pollutants, underscores the urgent need for effective diagnostic solutions. Additionally, advancements in diagnostic technologies, such as imaging modalities like CT scans and MRI, as well as the emergence of molecular diagnostics and biomarker testing, have revolutionized the detection and management of lung cancer.
Rising awareness campaigns and government initiatives aimed at early detection and screening programs have further fueled market expansion. These efforts emphasize the importance of timely diagnosis in improving patient outcomes and reducing mortality rates associated with lung cancer. Furthermore, the growing adoption of minimally invasive procedures for biopsy and tissue sampling, coupled with the integration of artificial intelligence (AI) and machine learning algorithms in diagnostic platforms, are enhancing accuracy and efficiency in lung cancer detection.
The global lung cancer diagnostics market is characterized by intense competition and a diverse range of market players, including diagnostic laboratories, medical device manufacturers, and healthcare providers. Companies are increasingly focusing on research and development activities to introduce innovative diagnostic solutions, thereby augmenting their market presence. With the continuous evolution of diagnostic technologies and the increasing emphasis on personalized medicine, the lung cancer diagnostics market is poised for substantial growth in the foreseeable future.
Global Lung Cancer Diagnostics Market Recent Developments
-
In March 2023, Roche announced approval from the U.S. FDA for VENTANA PD-L1 (SP263) Assay. SP263 helps in advising immunotherapy non-small cell lung cancer (NSCLC) patients.
-
In June 2024, Getinge launched the Soltera® low-temperature sterilization system, utilizing hydrogen peroxide vapor technology to safely sterilize heat-sensitive medical instruments. Concurrently, Belimed introduced its H2O2 Sterilization Technology, enhancing low-temperature sterilizers' efficiency while promoting safety and sustainability, aligning with the demand for eco-friendly sterilization solutions.
Segment Analysis
The global lung cancer diagnostics market is segmented based on lung cancer type into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is the more prevalent form of lung cancer, accounting for approximately 85% of all lung cancer cases. Due to its higher incidence, the demand for diagnostic tests for NSCLC is significantly greater. On the other hand, SCLC, although less common, requires specialized diagnostic approaches due to its aggressive nature and rapid progression. As a result, the market for diagnostics tailored to SCLC, such as molecular tests, is also growing, though at a smaller scale compared to NSCLC diagnostics.
In terms of diagnostic tests, the market is categorized into imaging tests, sputum cytology, biopsy, molecular tests, and others. Imaging tests, including CT scans and PET scans, remain the cornerstone of initial diagnosis, helping to identify tumors and stage the cancer. Sputum cytology and biopsy are essential for confirming diagnosis and determining the cancer's subtype. Meanwhile, molecular tests are gaining traction due to their ability to identify specific genetic mutations and biomarkers that can guide targeted therapies. Other diagnostic methods, such as liquid biopsy, are emerging as less invasive options that show promise for early detection and monitoring.
The end-use for the global lung cancer diagnostics market includes hospitals and clinics, diagnostic laboratories, and others. Hospitals and clinics dominate the market due to their capacity to offer comprehensive diagnostic services, including imaging and biopsy procedures, coupled with the availability of specialized healthcare professionals. Diagnostic laboratories also play a crucial role, particularly in advanced molecular testing, which requires high-tech equipment and expertise. Additionally, the market is witnessing a rise in diagnostic services offered by home care and mobile health platforms, providing more accessible options for patients in remote or underserved areas.
Global Lung Cancer Diagnostics Segment Analysis
In this report, the Global Lung Cancer Diagnostics Market has been segmented by Lung Cancer Type, Diagnostic Test, End Use and Geography.
Global Lung Cancer Diagnostics Market, Segmentation by Lung Cancer Type
The Global Lung Cancer Diagnostics Market has been segmented by Lung Cancer Type into Small cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC).
Small Cell Lung Cancer (SCLC) accounts for approximately 10-15% of all lung cancer cases. It is characterized by aggressive growth and early metastasis, often presenting at advanced stages, which poses challenges for diagnosis and treatment. However, recent advancements in diagnostic techniques such as liquid biopsy and next-generation sequencing (NGS) have improved the early detection of SCLC, facilitating prompt intervention and personalized treatment strategies.
Non-Small Cell Lung Cancer (NSCLC) comprises the majority (around 85-90%) of lung cancer cases. NSCLC encompasses several histological subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype presents unique diagnostic challenges and therapeutic considerations, necessitating precise diagnostic approaches tailored to individual patient profiles. The emergence of novel biomarkers and imaging modalities, coupled with the integration of artificial intelligence (AI) in diagnostic workflows, has revolutionized NSCLC diagnosis, enabling more accurate prognostication and treatment selection.
Market players are increasingly investing in research and development to innovate diagnostic solutions tailored to the distinct characteristics of SCLC and NSCLC. Collaborations between industry stakeholders and academic institutions are fostering the development of cutting-edge technologies aimed at enhancing the sensitivity and specificity of lung cancer diagnostics. Moreover, initiatives focused on raising awareness about the importance of early detection and screening programs are expected to drive market growth by expanding the pool of diagnosed patients eligible for timely interventions and improved clinical outcomes.
Global Lung Cancer Diagnostics Market, Segmentation by Diagnostic Test
The Global Lung Cancer Diagnostics Market has been segmented by Diagnostic Test into Imaging Test, Sputum cytology, Biopsy, Molecular tests and Others.
Imaging tests, such as chest X-rays, computed tomography (CT) scans, and magnetic resonance imaging (MRI), are among the most common diagnostic tools utilized for identifying lung abnormalities. These non-invasive techniques enable healthcare professionals to visualize the lungs and detect any suspicious nodules or masses that may indicate the presence of cancer. With ongoing advancements in imaging technology, these tests continue to improve in terms of sensitivity and accuracy.
Sputum cytology is another important diagnostic test used in the evaluation of lung cancer. It involves the examination of sputum samples under a microscope to detect abnormal cells, including cancerous cells. While sputum cytology is less invasive compared to other procedures, its sensitivity may vary, and it may not always provide definitive results, particularly in early-stage lung cancer cases.
Biopsy remains a gold standard in lung cancer diagnosis, allowing for the direct examination of tissue samples to confirm the presence of cancer cells. This invasive procedure involves the removal of a small portion of lung tissue for laboratory analysis. Various biopsy techniques, such as bronchoscopy, needle biopsy, and surgical biopsy, are available depending on the location and accessibility of the suspicious lesion.
Molecular tests, including genetic and molecular profiling assays, have emerged as valuable tools in lung cancer diagnostics. These tests analyze specific genetic mutations, biomarkers, or gene expression patterns associated with lung cancer, aiding in personalized treatment decisions and prognostic assessments. Molecular testing can help identify targeted therapies and predict patient response to certain treatments, leading to more tailored and effective management strategies.
Other ancillary procedures and tests may also contribute to the comprehensive evaluation of lung cancer, including blood tests, pulmonary function tests, and positron emission tomography (PET) scans. As the understanding of lung cancer biology continues to evolve and technological innovations progress, the landscape of lung cancer diagnostics is expected to further expand, offering more sophisticated and precise methods for early detection and personalized treatment approaches.
Global Lung Cancer Diagnostics Market, Segmentation by End Use
The Global Lung Cancer Diagnostics Market has been segmented by End Use into Hospitals and Clinics, Diagnostic Laboratories and, Others.
The global lung cancer diagnostics market is segmented by end use into several categories, each with its unique role in the healthcare system. Hospitals and clinics form one of the key segments, where the majority of lung cancer diagnostic procedures take place. These institutions are equipped with advanced medical technologies and staffed with professionals capable of performing a wide range of diagnostic tests, such as imaging scans, biopsies, and molecular testing. The high patient volume and access to specialized equipment in hospitals and clinics make them primary centers for early detection and diagnosis of lung cancer.
Another important segment is diagnostic laboratories, which play a crucial role in providing specialized testing services. These labs offer advanced diagnostic tools, including pathology services, genetic testing, and liquid biopsy analysis. Diagnostic laboratories are often the go-to resource for confirming the results from initial screenings or imaging tests performed in hospitals or clinics. With increasing demand for precise and accurate diagnostics, these laboratories are seeing a growing need for cutting-edge technology and skilled professionals who can interpret complex data to help determine the presence and type of lung cancer.
The others segment includes various other healthcare settings, such as research institutions, homecare settings, and mobile diagnostic units, which contribute to the overall diagnostic landscape. These alternatives provide specialized services, such as research-focused diagnostic tests or at-home testing kits for early lung cancer detection. The growing trend toward personalized medicine and remote healthcare is driving the expansion of this segment, as more patients seek convenient options for diagnosis and treatment monitoring outside of traditional healthcare facilities.
Global Lung Cancer Diagnostics Market, Segmentation by Geography
In this report, the Global Lung Cancer Diagnostics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Lung Cancer Diagnostics Market Share (%), by Geographical Region, 2024
North America holds a prominent share in the global lung cancer diagnostics market, attributed to factors such as the presence of well-established healthcare infrastructure, high adoption rates of advanced diagnostic technologies, and increasing government initiatives for cancer screening and awareness programs. Additionally, the rising prevalence of lung cancer in the region further fuels market growth.
Europe follows North America in terms of market share, with countries like Germany, the UK, and France leading the region's lung cancer diagnostics market. Factors such as the growing aging population, increasing tobacco consumption, and favorable reimbursement policies for diagnostic procedures contribute to the market's expansion in Europe.
The Asia Pacific region is experiencing rapid growth in the lung cancer diagnostics market, driven by factors such as the rising prevalence of lung cancer, improving healthcare infrastructure, and growing investments in healthcare R&D. Countries like China, Japan, and India are witnessing significant market growth due to the increasing adoption of early cancer detection techniques and rising healthcare expenditure.
In the Middle East and Africa region, the lung cancer diagnostics market is also growing steadily, albeit at a slower pace compared to other regions. Factors such as the improving healthcare infrastructure, rising awareness about cancer screening programs, and increasing government initiatives to control cancer prevalence contribute to market growth in this region.
Latin America represents a growing market for lung cancer diagnostics, driven by factors such as the rising incidence of lung cancer, improving access to healthcare services, and increasing investments in healthcare infrastructure. Countries like Brazil and Mexico are witnessing significant market growth due to the implementation of screening programs and the adoption of advanced diagnostic technologies.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Lung Cancer Diagnostics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers:
- Advanced screening technologies
- Rising incidence of lung cancer
- Growing awareness and early detection
-
Technological advancements in diagnostics- Technological advancements have played a pivotal role in shaping the landscape of lung cancer diagnostics, driving significant improvements in early detection, accuracy, and treatment outcomes. One notable advancement is the development of liquid biopsy techniques, which offer a minimally invasive alternative to traditional tissue biopsies. Liquid biopsies analyze circulating tumor cells, cell-free DNA, and other biomarkers present in bodily fluids, providing valuable information about tumor genetics and progression without the need for invasive procedures. This approach not only facilitates early detection but also enables real-time monitoring of treatment response and disease progression, leading to more personalized and effective treatment strategies.
The integration of artificial intelligence (AI) and machine learning algorithms has revolutionized lung cancer diagnostics by enhancing the accuracy and efficiency of image interpretation and data analysis. AI-powered imaging technologies can analyze medical images such as CT scans and X-rays with unprecedented speed and accuracy, enabling radiologists to identify subtle abnormalities and classify tumors more accurately. These advanced analytics tools also help clinicians predict patient outcomes, stratify risk, and tailor treatment plans based on individual patient characteristics, ultimately improving clinical decision-making and patient outcomes.
In addition to liquid biopsies and AI-driven diagnostics, the emergence of novel biomarkers and molecular profiling technologies has expanded the repertoire of diagnostic tools available for lung cancer detection and characterization. These innovative approaches enable clinicians to assess tumor heterogeneity, identify potential therapeutic targets, and predict treatment response with greater precision. By leveraging a combination of advanced technologies and multidisciplinary approaches, the global lung cancer diagnostics market continues to evolve, driving improvements in patient care, survival rates, and overall disease management.
Restraints:
- High costs of diagnostic procedures
- Limited accessibility in rural areas
- Regulatory hurdles for new technologies
-
Lack of skilled healthcare professionals- The global lung cancer diagnostics market has witnessed significant growth in recent years, driven by factors such as increasing prevalence of lung cancer, advancements in diagnostic technologies, and rising awareness about early detection. However, one of the key challenges facing this market is the lack of skilled healthcare professionals proficient in interpreting diagnostic tests and providing accurate diagnoses. Despite the availability of sophisticated diagnostic tools such as computed tomography (CT) scans, positron emission tomography (PET) scans, and molecular testing, the effectiveness of these technologies heavily relies on the expertise of healthcare professionals in accurately interpreting the results.
The complexity of lung cancer diagnostics necessitates a multidisciplinary approach involving radiologists, pathologists, oncologists, and other specialists. However, the shortage of skilled professionals in these fields, especially in certain regions or healthcare settings, poses a significant barrier to timely and accurate diagnosis. This shortage is exacerbated by factors such as high patient volumes, limited resources, and inadequate training programs. As a result, there is a growing concern regarding the potential for misdiagnosis or delayed diagnosis, which can have serious implications for patient outcomes and healthcare costs.
Addressing the issue of the lack of skilled healthcare professionals in lung cancer diagnostics requires a multifaceted approach. This includes investing in comprehensive training programs, increasing access to specialized education and certification courses, incentivizing professionals to specialize in oncology and related fields, and leveraging technology to augment diagnostic capabilities and facilitate remote consultation and collaboration among experts. By addressing these challenges, stakeholders can improve the quality and efficiency of lung cancer diagnostics, ultimately leading to better outcomes for patients and a more sustainable healthcare system.
Opportunities:
- Emerging markets expansion
- Personalized medicine and targeted therapies
- Integration of AI in diagnostics
-
Collaborative research and development efforts- The global lung cancer diagnostics market has witnessed significant growth, driven by advancements in technology, increasing awareness about early detection, and rising incidence of lung cancer worldwide. In this dynamic landscape, collaborative research and development efforts have emerged as pivotal drivers of innovation. Pharmaceutical companies, diagnostic laboratories, academic institutions, and government agencies are increasingly partnering to enhance the efficacy and accessibility of lung cancer diagnostics.
One key area of collaboration is in the development of novel biomarkers and diagnostic tools. By pooling resources and expertise, stakeholders can accelerate the discovery and validation of biomarkers that enable early detection, predict treatment response, and monitor disease progression. For instance, collaborative efforts have led to the identification of circulating tumor cells, circulating tumor DNA, and exosomal RNA as promising biomarkers for lung cancer diagnosis and monitoring. Moreover, these partnerships facilitate the translation of research findings into clinical applications, ensuring that innovative diagnostic technologies reach patients in a timely manner.
Collaborative research initiatives play a crucial role in advancing imaging technologies for lung cancer diagnosis. By combining computational algorithms, machine learning, and imaging modalities such as CT, MRI, and PET scans, researchers can develop more accurate and non-invasive diagnostic tools. These efforts not only improve the sensitivity and specificity of lung cancer detection but also enable early-stage diagnosis, which is critical for improving patient outcomes. Furthermore, collaboration fosters standardization and validation of imaging protocols, ensuring consistency across healthcare settings and facilitating seamless integration into clinical practice. Overall, collaborative research and development efforts are essential for driving innovation and improving the effectiveness of lung cancer diagnostics, ultimately benefiting patients and healthcare systems worldwide.
Competitive Landscape Analysis
Key players in Global Lung Cancer Diagnostics Market include:
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc
- Qiagen N.V
- Illumina, Inc
- Biocept, Inc
- Agilent Technologies, Inc
- Myriad Genetics, Inc
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Lung Cancer Type
- Market Snapshot, By Diagnostic Test
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global Lung Cancer Diagnostics Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Advanced screening technologies
- Rising incidence of lung cancer
- Growing awareness and early detection
- Technological advancements in diagnostics
- Restraints
- High costs of diagnostic procedures
- Limited accessibility in rural areas
- Regulatory hurdles for new technologies
- Lack of skilled healthcare professionals
- Opportunities
- Emerging markets expansion
- Personalized medicine and targeted therapies
- Integration of AI in diagnostics
- Collaborative research and development efforts
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Lung Cancer Diagnostics Market, By Lung Cancer Type, 2021 - 2031 (USD Million)
- Small cell lung cancer (SCLC)
- Non-small cell lung cancer (NSCLC)
- Global Lung Cancer Diagnostics Market, By Diagnostic Test, 2021 - 2031 (USD Million)
- Imaging Test
- Sputum cytology
- Biopsy
- Molecular tests
- Others
- Global Lung Cancer Diagnostics Market, By End Use, 2021 - 2031 (USD Million)
- Hospitals and Clinics
- Diagnostic Laboratories
- Others
- Global Lung Cancer Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Lung Cancer Diagnostics Market, By Lung Cancer Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc
- Qiagen N.V
- Illumina, Inc
- Biocept, Inc
- Agilent Technologies, Inc
- Myriad Genetics, Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market